Our Team

Each Partner brings extensive industry knowledge, unrivaled relationships and substantial deal experience, resulting in a team of the industry's most sought after advisors

Jason W. Lee

Jason Lee joined Centerview Partners in 2012 and is a Partner in the San Francisco office. At Centerview, Mr. Lee has advised a broad range of life science companies across strategic advisory assignments and transactions exceeding $130 billion in value.

Mr. Lee’s recent notable healthcare transactions include advising Immunomedics on its sale to Gilead for $21 billion, Array BioPharma on its sale to Pfizer for $11.8 billion, AveXis on its sale to Novartis for $8.7 billion, GW Pharmaceuticals on its sale to Jazz Pharmaceuticals for $7.2 billion, Tesaro on its sale to GSK for $5.1 billion, Forty Seven Therapeutics on its sale to Gilead for $4.9 billion, Dicerna Pharmaceuticals on its sale to Novo Nordisk for $3.3 billion, ArQule on its sale to Merck for $2.7 billion, Ra Pharma on its sale to UCB for $2.5 billion, Synthorx on its sale to Sanofi for $2.5 billion, Peloton Therapeutics on its sale to Merck for up to $2.2 billion, Constellation Pharmaceuticals on its sale to MorphoSys for $1.7 billion, ARMO on its sale to Eli Lilly for $1.6 billion, Imago Biosciences on its sale to Merck for $1.3 billion, Syntimmune on its sale to Alexion for up to $1.2 billion, Eidos Therapeutics on its $1.1 billion sale of the publicly-traded minority shares to BridgeBio, Lengo Therapeutics on its sale to Blueprint for up to $465 million, Pionyr on its option transaction with Gilead.

Other notable transactions include advising Pharmacyclics on its sale to AbbVie for $21 billion, Kite Pharma on its sale to Gilead for $11.9 billion, Onyx on its sale to Amgen for $10.4 billion, InterMune on its sale to Roche for $8.9 billion, Dyax on its sale to Shire for $6.6 billion, Avanir on its sale to Otsuka for $3.5 billion, Relypsa on its sale to Galenica for $1.5 billion, Cadence on its sale to Mallinckrodt for $1.3 billion, MAP Pharmaceuticals on its sale to Allergan for $1 billion, Optimer and Trius on their sale to Cubist for $0.8 billion and $0.8 billion, respectively, Raptor on its sale to Horizon for $0.8 billion, XenoPort on its sale to Arbor for $500 million.

Mr. Lee holds an M.B.A. from Cornell University and a B.S. in Microbiology and Molecular Genetics from University of California, Los Angeles.
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Centerview is honored to partner with leading charitable organizations in active support of our charities:

  • Arts Connection
  • NY Cares
  • Bottomless Closet
Serta Simmons Bedding, LLC
Announced: Q1 2023
Status: Pending

Financial advisor to the ad hoc group of priority term loan lenders on Serta Simmons Bedding's chapter 11 filing and Restructuring Support Agreement
View All
New York

Centerview Partners LLC

31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax

Centerview Partners UK LLP

100 Pall Mall

3rd Floor

London SW1Y 5NQ

02074099700 | Tel
02074099704 | Fax

Centerview Partners France SCS

16 Avenue Matignon

4th Floor

Paris 75008

0180200620 | Tel
0180200621 | Fax
Palo Alto

Centerview Partners LLC

600 Ramona St.

Suite 300

Palo Alto, California 94301

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC

555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax

Copyright © 2008 - 2023 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC